Comparisons

GLP-1 vs Phentermine: Which Is Better for Long-Term Weight Loss?

GLP-1 Companion · 9 min read

Phentermine and GLP-1 receptor agonists represent two very different eras of obesity pharmacotherapy. Phentermine has been in use since 1959 and remains one of the most commonly prescribed weight-loss medications in the United States by sheer prescription volume. GLP-1 medications like semaglutide and tirzepatide entered the obesity treatment landscape more recently but have rapidly become the clinical standard of care. Comparing the two requires understanding not just efficacy numbers but also mechanism, safety profile, approved duration of use, and cost.

How Phentermine Works

Phentermine is a sympathomimetic amine — structurally related to amphetamine — that works primarily by stimulating the release of norepinephrine in the hypothalamus. This norepinephrine surge activates the fight-or-flight response and suppresses appetite through adrenergic pathways. Phentermine also has modest dopaminergic and serotonergic activity, which may contribute to its appetite-suppressing effects. The net result is reduced hunger and, to a lesser extent, increased energy expenditure through mild sympathetic nervous system activation.

Because phentermine acts on the central nervous system through catecholamine pathways rather than through gut-brain hormonal signaling, it does not slow gastric emptying, does not reduce post-meal satiety through GLP-1 receptor activation, and has no effect on blood glucose regulation or insulin secretion.

How GLP-1 Medications Work

GLP-1 receptor agonists mimic the action of endogenous glucagon-like peptide-1, a hormone released by intestinal L-cells after eating. They bind GLP-1 receptors throughout the body — including the hypothalamus, brainstem, stomach, pancreas, and heart — to produce multiple simultaneous effects: reduced appetite and food cravings, slowed gastric emptying (prolonging fullness), increased insulin secretion in response to food, suppressed glucagon release, and direct effects on reward circuitry that reduce food noise. Tirzepatide additionally acts on GIP receptors, which appears to enhance weight loss beyond GLP-1 agonism alone.

FDA Approval and Intended Duration of Use

This is one of the most clinically significant differences between phentermine and GLP-1 medications. Phentermine is FDA-approved for short-term use only — defined as typically a few weeks, with most prescribing guidelines recommending no longer than 12 weeks. This restriction exists because of concerns about cardiovascular effects, potential for habituation, and the lack of long-term safety data. Despite these label restrictions, off-label longer-term use does occur in clinical practice.

GLP-1 medications approved for obesity — Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3.0 mg) — are approved for chronic, long-term management of obesity. Clinical trials supporting their approval ran for 68 to 72 weeks, and real-world data extending to several years of continuous use has been accumulating since their launch. The SELECT trial demonstrated that semaglutide 2.4 mg provided sustained cardiovascular benefits over approximately 40 months, supporting long-term use in appropriate patients.

Weight Loss Comparison

Clinical trial data shows a meaningful efficacy gap between phentermine and modern GLP-1 agents.

• Phentermine (monotherapy, short-term): average weight loss of 5 to 8 percent of initial body weight over 12 weeks
• Semaglutide 2.4 mg (Wegovy, STEP 1 trial): average weight loss of approximately 14.9 percent over 68 weeks
• Tirzepatide 15 mg (Zepbound, SURMOUNT-1 trial): average weight loss of approximately 20.9 percent over 72 weeks
• Tirzepatide vs semaglutide head-to-head (SURMOUNT-5, NEJM 2025): tirzepatide produced ~47% greater relative weight loss than semaglutide
• Qsymia (phentermine/topiramate extended-release): average weight loss of 9 to 11 percent — better than phentermine alone but less than GLP-1 agents

Side Effects and Safety Profile

The side effect profiles of phentermine and GLP-1 medications are quite different, reflecting their distinct mechanisms.

Phentermine Side Effects

• Increased heart rate and blood pressure — a significant concern in patients with existing cardiovascular disease
• Insomnia and sleep disturbance — common, especially if taken in the afternoon or evening
• Dry mouth, constipation, and decreased appetite (also a feature, not just a side effect)
• Anxiety, irritability, and nervousness from sympathetic nervous system stimulation
• Risk of pulmonary hypertension and valvular heart disease with long-term use (the rationale for the short-term approval)
• Schedule IV controlled substance: potential for psychological dependence
• Contraindicated in patients with cardiovascular disease, hyperthyroidism, glaucoma, history of drug abuse, and during pregnancy

GLP-1 Medication Side Effects

• Nausea, vomiting, diarrhea, and constipation — most common, usually peak during dose escalation
• No meaningful increase in heart rate at therapeutic doses (slight modest increase of 1-4 bpm observed in some trials)
• Demonstrated cardiovascular benefit in the SELECT trial (semaglutide) — not a cardiovascular risk
• Rare but serious: pancreatitis, gallbladder disease, and theoretical thyroid C-cell tumor risk based on animal models
• Not a controlled substance; no abuse potential
• Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2

Cardiovascular Safety: A Critical Distinction

For patients with or at risk for cardiovascular disease, the safety distinction between phentermine and GLP-1 agents is clinically decisive. Phentermine increases heart rate and blood pressure through sympathetic activation, making it generally contraindicated in patients with hypertension, coronary artery disease, arrhythmias, or heart failure. GLP-1 medications, by contrast, have demonstrated cardiovascular protection in large outcome trials. Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20 percent in the SELECT trial, leading to FDA approval for cardiovascular risk reduction in March 2024. This benefit extended to patients without diabetes — a population that had previously lacked cardiovascular outcome data for any obesity medication.

Qsymia: The Phentermine-Topiramate Bridge

Qsymia (phentermine plus extended-release topiramate) was FDA-approved in 2012 and represents a middle ground between traditional phentermine use and GLP-1 therapy. Adding topiramate — an anticonvulsant with weight-loss properties — to phentermine allows lower doses of each drug, reducing cardiovascular stimulation while extending efficacy beyond what either agent achieves alone. Qsymia produces average weight loss of 9 to 11 percent, which is better than phentermine monotherapy but still meaningfully less than semaglutide or tirzepatide. Qsymia is approved for longer-term use than phentermine alone, though it carries its own concerns including cognitive side effects from topiramate and a teratogenicity risk requiring a REMS program. For some patients, particularly those who cannot tolerate GLP-1 gastrointestinal side effects or who face significant cost barriers, Qsymia occupies a valid therapeutic niche.

Who Still Uses Phentermine in 2026?

Despite the clinical advantages of GLP-1 medications, phentermine retains a meaningful place in the treatment landscape for specific situations.

• Cost-driven decisions: Phentermine is generic and costs as little as $15 to $30 per month — a fraction of the cost of branded GLP-1 medications
• Short-term initiation: Some clinicians use phentermine to achieve rapid early weight loss while awaiting GLP-1 insurance approval or prior authorization
• GLP-1 intolerance: Patients who cannot tolerate GLP-1 gastrointestinal side effects may find phentermine better tolerated
• Formulary barriers: In settings where GLP-1 medications are not covered, phentermine provides a pharmacological option
• Combination regimens: A small number of clinicians use phentermine alongside GLP-1 agents in carefully selected patients, though this is off-label

The Bottom Line

For most patients seeking long-term, sustained weight loss with a favorable safety profile, GLP-1 medications are the superior choice. They produce significantly greater weight loss, are approved for chronic use, and in the case of semaglutide, provide demonstrated cardiovascular protection. Phentermine retains a role in cost-limited situations and short-term use cases, but its cardiovascular stimulation, controlled substance status, and short-term-only approval limit its utility for the long-term obesity management that most patients need. The choice between these options is ultimately individualized — and should account for your cardiovascular history, cost situation, tolerance for side effects, and treatment goals.

GLP-1 medications represent a fundamental shift in how obesity is treated — not just suppressing appetite temporarily, but resetting the hormonal environment that drives excess weight in the first place. Phentermine addresses hunger through a blunter, shorter-acting mechanism with greater cardiovascular risk.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.